Back to top

Biolase’s Strong Q4 Performance and Positive 2024 Outlook Affirm Buy Rating

Biolase (BIOL) has received a new Buy rating, initiated by Maxim Group analyst, Anthony Vendetti. Anthony Vendetti’s rating is based on a comprehen...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Biolase, Inc. (BIOL)